Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.
Market Dynamics
Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.
Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.
Key features of the study:
- This report provides an in-depth analysis of global bulimia nervosa treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global bulimia nervosa treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market
Detailed Segmentation:
- Global Bulimia Nervosa Treatment Market, By Treatment Type:
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- Global Bulimia Nervosa Treatment Market, By Route of Administration:
- Global Bulimia Nervosa Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bulimia Nervosa Treatment Market, By Region:
- North America
- By Country
- By Treatment Type:
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-Drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Treatment Type:
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-Drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Treatment Type:
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-Drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Treatment Type:
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-Drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Treatment Type:
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-Drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Treatment Type:
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-Drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Allergan, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- AstraZeneca plc
- Alembic Pharmaceuticals Ltd
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Reddy’s Laboratories Limited
- Lupin Pharmaceuticals, Inc.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
“*” marked represents similar segmentation in other categories in the respective section.
